{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:30Z","timestamp":1793042130630,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yale Cancer Center\u2019s Team Challenge Research Award"},{"name":"Yale Cancer Center\u2019s Class of 1961 Cancer Research Award"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262377"],"award-info":[{"award-number":["R01CA262377"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yale Chenevert Family Brain Tumor Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with lung cancer brain metastases can benefit from immune checkpoint inhibitors (ICI). However, intracranial responses are often limited and not always concordant with activity seen in extracranial disease. Defects in IFN\u03b3 signaling and HLA class-I antigen presentation machinery (APM) on malignant cells can drive immune evasion and ICI resistance, and have traditionally been viewed as interdependent. The possible role of these alterations in non-small cell lung cancer (NSCLC) brain progression remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using multiplex quantitative immunofluorescence, we measured and spatially mapped IFN\u03b3 signaling markers (pSTAT1 and IRF1) and multiple HLA class-I APM components (\u03b22M, PSMB8, PSMB9, PSMB10, TAP1, TAP2, Tapasin, Calreticulin, and ERp57) in cancer cells and neighboring non-malignant stromal cells from two patient cohorts, including primary tumors, intra- and extra-cranial NSCLC metastases. We also studied tumor-infiltrating lymphocyte (TILs) subpopulations in the cohorts, performed whole transcriptomic analysis of parental human NSCLC H2030 cells and their brain metastatic counterpart H2030-BrM3, and expanded the results using spatial transcriptomics of human tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found comparable levels of IFN\u03b3 signaling markers in primary and metastatic lesions and marked downregulation of multiple APM components in metastases, some of which were restricted to the brain. Downregulation of HLA class-I APM components was associated with reduced effector TILs and worse survival. Analysis of human parental H2030 and brain metastatic H2030-BrM3 lung adenocarcinoma cells showed comparable signaling responses after IFN\u03b3 stimulation and reduced HLA class-I APM markers in metastatic cells. Transcriptomic analysis of primary\/metastatic cells and human tumors identified differential expression of multiple genes associated with HLA class-I APM downregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results reveal that APM downregulation is a prominent feature of NSCLC brain metastases, is independent from local IFN\u03b3 signaling defects and is associated with unfavorable clinical features. We also identified candidate modulators of the APM pathway in brain metastases with potential translational significance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-026-02687-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:05:17Z","timestamp":1779980717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFN\u03b3 signaling defects"],"prefix":"10.1186","volume":"25","author":[{"given":"Noelia","family":"Vilari\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Lopez","family":"de Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Villalba-Esparza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barani Kumar","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hijazo-Pechero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishu","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ramos-Paradas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don X.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"4","key":"2687_CR1","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, et al. Non\u2013small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018;19(4):e373\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.007.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"2687_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","volume":"4","author":"M Valiente","year":"2018","unstructured":"Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, et al. The evolving landscape of brain metastasis. Trends Cancer. 2018;4(3):176\u201396. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.003.","journal-title":"Trends Cancer"},{"issue":"8","key":"2687_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtocrr.2021.100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Herbst RS, de Castro G, Hui R, Peled N, Kim DW, et al. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1\u2013Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Reports. 2021;2(8):1\u201311.","journal-title":"JTO Clin Res Reports"},{"key":"2687_CR4","doi-asserted-by":"crossref","unstructured":"Kilickap S, \u00d6zg\u00fcro\u011flu M, Sezer A, G\u00fcm\u00fc\u015f M, Bondarenko I, Gogishvili M, et al. Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non\u2013small cell lung cancer with programmed cell death-ligand 1 \u226550%. Cancer. 2025;131(10).","DOI":"10.1002\/cncr.35864"},{"issue":"8","key":"2687_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, et al. Systemic and intracranial outcomes with first-line Nivolumab plus Ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1. J Thorac Oncol. 2023;18(8):1055\u201369. https:\/\/doi.org\/10.1016\/j.jtho.2023.04.021.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2687_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG, Ciuleanu TE, Cobo M, Bennouna J, Schenker M, Cheng Y, et al. First-line Nivolumab plus Ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol. 2023;18(2):204\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.014.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2687_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell SF, Rodr\u00edguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, et al. Outcomes with Pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021;16(11):1883\u201392. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.020.","journal-title":"J Thorac Oncol"},{"key":"2687_CR8","doi-asserted-by":"crossref","unstructured":"Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario Garc\u00eda Campelo M, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer. 2023;11(2).","DOI":"10.1136\/jitc-2022-006127"},{"key":"2687_CR9","doi-asserted-by":"publisher","first-page":"102067","DOI":"10.1016\/j.ctrv.2020.102067","volume":"89","author":"N Vilari\u00f1o","year":"2020","unstructured":"Vilari\u00f1o N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev. 2020;89:102067. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102067.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"2687_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(20)30111-X.","journal-title":"Lancet Oncol"},{"issue":"28","key":"2687_CR11","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal E, Rodr\u00edguez-Abreu D, Sim\u00f3 M, Massut\u00ed B, Juan O, Huidobro G, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17\/05). J Clin Oncol. 2023;41(28):4478\u201385.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2687_CR12","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jtho.2025.09.044","volume":"20","author":"E Nadal","year":"2025","unstructured":"Nadal E, Cantero A, Paz-Ares L, Ortega AL, Barba A, Iranzo P, et al. OA05.03 NIVIPI-Brain: Phase 2 study of Nivolumab + Ipilimumab combined with chemotherapy in NSCLC with synchronous brain metastases. J Thorac Oncol. 2025;20(10):S19\u201320. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.044.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2687_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326\u201341. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.009.","journal-title":"Cancer Cell"},{"issue":"9","key":"2687_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","volume":"30","author":"Y Kudo","year":"2019","unstructured":"Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol. 2019;30(9):1521\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdz207.","journal-title":"Ann Oncol"},{"issue":"1","key":"2687_CR15","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27(1):1953\u20138.","journal-title":"Ann Oncol"},{"issue":"10","key":"2687_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-002684","volume":"9","author":"BY Lu","year":"2021","unstructured":"Lu BY, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, et al. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. J Immunother Cancer. 2021;9(10):1\u20137.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2687_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"2","key":"2687_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397-404.e9. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069.","journal-title":"Cell"},{"issue":"2","key":"2687_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"12","key":"2687_CR20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"12","key":"2687_CR21","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1078-0432.CCR-16-1946","volume":"23","author":"C Pereira","year":"2017","unstructured":"Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, et al. Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. Clin Cancer Res. 2017;23(12):3203\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2687_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","volume":"7","author":"L Maggs","year":"2021","unstructured":"Maggs L, Sadagopan A, Moghaddam AS, Ferrone S. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends Cancer. 2021;7(12):1089\u2013101. https:\/\/doi.org\/10.1016\/j.trecan.2021.07.006.","journal-title":"Trends Cancer"},{"issue":"10","key":"2687_CR23","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1158\/1078-0432.CCR-20-3655","volume":"27","author":"IJ Datar","year":"2021","unstructured":"Datar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, et al. Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non\u2013small cell lung cancer. Clin Cancer Res. 2021;27(10):2837\u201347.","journal-title":"Clin Cancer Res"},{"key":"2687_CR24","doi-asserted-by":"crossref","unstructured":"Moutafi MK, Bates KM, Aung TN, Milian RG, Xirou V, Vathiotis IA, et al. High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2024;12(6).","DOI":"10.1136\/jitc-2024-009039"},{"issue":"3","key":"2687_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/dju435","volume":"107","author":"KA Schalper","year":"2015","unstructured":"Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107(3):1\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2687_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/labinvest.2013.130","volume":"94","author":"V Velcheti","year":"2014","unstructured":"Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig. 2014;94(1):107\u201316. https:\/\/doi.org\/10.1038\/labinvest.2013.130.","journal-title":"Lab Investig"},{"issue":"11","key":"2687_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm791","volume":"8","author":"RL Camp","year":"2002","unstructured":"Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323\u20137.","journal-title":"Nat Med"},{"key":"2687_CR28","doi-asserted-by":"publisher","unstructured":"Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, et al. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer. 2025;24(1). Available from: https:\/\/doi.org\/10.1186\/s12943-025-02276-z.","DOI":"10.1186\/s12943-025-02276-z"},{"key":"2687_CR29","doi-asserted-by":"crossref","unstructured":"Nguyen DX, Chiang AC, Zhang XH-F, Kim JY, Kris MG, Ladanyi M, et al. WNT\/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis. Cell. 2009;138(1):51\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19576624. Cited 2018 May 9.","DOI":"10.1016\/j.cell.2009.04.030"},{"issue":"7","key":"2687_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"1","key":"2687_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2009","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"12","key":"2687_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):1\u201321.","journal-title":"Genome Biol"},{"issue":"1","key":"2687_CR33","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2687_CR34","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"2687_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","volume":"19","author":"S Murata","year":"2018","unstructured":"Murata S, Takahama Y, Kasahara M, Tanaka K. The immunoproteasome and thymoproteasome: functions, evolution and human disease. Nat Immunol. 2018;19(9):923\u201331. https:\/\/doi.org\/10.1038\/s41590-018-0186-z.","journal-title":"Nat Immunol"},{"issue":"12","key":"2687_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10123587","volume":"10","author":"SC Tripathi","year":"2021","unstructured":"Tripathi SC, Vedpathak D, Ostrin EJ. The functional and mechanistic roles of immunoproteasome subunits in cancer. Cells. 2021;10(12):1\u201322.","journal-title":"Cells"},{"issue":"12","key":"2687_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022;22(12):751\u201364.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2687_CR38","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149(10):8131\u201341. https:\/\/doi.org\/10.1007\/s00432-023-04737-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2687_CR39","doi-asserted-by":"crossref","unstructured":"Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C, Ferrone S. HLA Class-I APM Upregulation by Anti-Cancer Therapies in the Era of Checkpoint Inhibitors: A Review. JAMA Oncol. 2022;8(3):462. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8930447\/.","DOI":"10.1001\/jamaoncol.2021.5970"},{"issue":"6","key":"2687_CR40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259-1271.e11.","journal-title":"Cell"},{"issue":"23_suppl","key":"2687_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1200\/JCO.2024.42.23_suppl.209","volume":"42","author":"J Han","year":"2024","unstructured":"Han J, Lin Y, Li W. Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance. J Clin Oncol. 2024;42(23_suppl):209\u2013209.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2687_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00262-020-02677-7","volume":"70","author":"JJ Failing","year":"2021","unstructured":"Failing JJ, Aubry MC, Mansfield AS. Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. Cancer Immunol Immunother. 2021;70(1):215\u20139. https:\/\/doi.org\/10.1007\/s00262-020-02677-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2687_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00109-024-02450-8","volume":"102","author":"M Liu","year":"2024","unstructured":"Liu M, Yang M, Zhang B, Xia S, Zhao J, Yan L, et al. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma. J Mol Med. 2024;102(7):899\u2013912. https:\/\/doi.org\/10.1007\/s00109-024-02450-8.","journal-title":"J Mol Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02687-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02687-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02687-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:22:46Z","timestamp":1786591366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02687-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2687"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02687-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.V. served as a consultant, advisor, or speaker for AstraZeneca, Takeda, Bristol-Myers Squibb, Roche, Merck, Boehringer-Ingelheim, Pfizer, and Novocure. A.C. served as a consultant for Bristol-Myers Squib. E.N. received research funding from Roche, Pfizer, Merck-Serono, and Bristol Myers Squibb, participated in advisory boards or received honoraria from Amgen, Abbvie, Apollomics, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, Genmab, Illumina, Johnson & Johnson, Lilly, Merck Sharp & Dohme (MSD), Merck-Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi, and Takeda, and received travel support from Roche, Takeda, Janssen, and MSD. D.X.N. served as consultant, advisor, or speaker for AstraZeneca and Daiichi Sankyo; received research funding from AstraZeneca. S.B.G. served as consulting or advisory board member for AstraZeneca, Eli Lilly, Daiichi-Sankyo, Johnson & Johnson, Summit Therapeutics, Merck, Regeneron, Bayer, Synthekine, and Tubulis. She received research funding from AstraZeneca, Boehringer Ingelheim, Mirati, and Adela. K.A.S. has served as a consultant or speaker Clinica Alemana Santiago, AstraZeneca, Janssen, Takeda, Agenus, Abbvie, Sanofi, GSK, Bristol-Myers Squibb, Roche, Molecular Templates, Merck, Dynamicure, Indaptus, Moderna Inc., Boehringer-Ingelheim, DAINA, Servier, NextPoint Therapeutics, Merus, PeerView, PER, Forefront Collaborative and Horizon CME; and receives grant\/research support from Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, Genentech\/Roche and NextPoint Therapeutics. Other authors report no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}